• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Association between plasma venetoclax trough levels and serum C-reactive protein levels in patients with acute myeloid leukemia treated with venetoclax plus azacitidine.

作者信息

Yasu Takeo, Gando Yoshito, Shirota Mikio, Kosugi Nobuharu, Kobayashi Masayuki

机构信息

Department of Medicinal Therapy Research, Pharmaceutical Education and Research Center, Meiji Pharmaceutical University, Tokyo, Japan.

Bokutoh Hospital-Meiji Pharmaceutical University Joint Research Center, Tokyo, Japan.

出版信息

Leuk Lymphoma. 2024 Jan;65(1):128-131. doi: 10.1080/10428194.2023.2264427. Epub 2024 Jan 10.

DOI:10.1080/10428194.2023.2264427
PMID:37797220
Abstract
摘要

相似文献

1
Association between plasma venetoclax trough levels and serum C-reactive protein levels in patients with acute myeloid leukemia treated with venetoclax plus azacitidine.维奈克拉联合阿扎胞苷治疗的急性髓系白血病患者血浆维奈克拉谷浓度与血清C反应蛋白水平之间的关联
Leuk Lymphoma. 2024 Jan;65(1):128-131. doi: 10.1080/10428194.2023.2264427. Epub 2024 Jan 10.
2
Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine.传统细胞遗传学对接受维奈克拉和地西他滨治疗的急性髓系白血病的预后影响
Leuk Lymphoma. 2021 Dec;62(14):3501-3505. doi: 10.1080/10428194.2021.1973675. Epub 2021 Sep 3.
3
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.在未经治疗的老年急性髓系白血病患者中，venetoclax 联合地西他滨或阿扎胞苷的安全性和初步疗效：一项非随机、开放标签、1b 期研究。
Lancet Oncol. 2018 Feb;19(2):216-228. doi: 10.1016/S1470-2045(18)30010-X. Epub 2018 Jan 12.
4
Overexposure to venetoclax is associated with prolonged-duration of neutropenia during venetoclax and azacitidine therapy in Japanese patients with acute myeloid leukemia.在接受 venetoclax 和阿扎胞苷治疗的日本急性髓系白血病患者中，venetoclax 暴露过度与中性粒细胞减少症的持续时间延长有关。
Cancer Chemother Pharmacol. 2024 Aug;94(2):285-296. doi: 10.1007/s00280-024-04673-5. Epub 2024 May 23.
5
Myeloid sarcoma of the urinary bladder as the presenting feature of secondary acute myeloid leukemia, successfully treated with venetoclax and azacitidine.膀胱髓系肉瘤作为继发性急性髓系白血病的首发表现，经维奈克拉和阿扎胞苷成功治疗。
Ann Hematol. 2024 Feb;103(2):671-672. doi: 10.1007/s00277-023-05529-3. Epub 2023 Nov 9.
6
Venetoclax with decitabine or azacitidine for AML.维奈托克联合地西他滨或阿扎胞苷治疗急性髓系白血病
Lancet Oncol. 2018 Dec;19(12):e672. doi: 10.1016/S1470-2045(18)30824-6. Epub 2018 Nov 1.
7
Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A.VIALE-A研究中接受维奈克拉和阿扎胞苷治疗的急性髓系白血病患者缓解后血细胞减少的管理
Am J Hematol. 2022 Nov;97(11):E416-E419. doi: 10.1002/ajh.26692. Epub 2022 Sep 16.
8
Venetoclax and azacitidine therapy in acute myeloid leukemia patients with severe renal impairment.维奈托克与阿扎胞苷联合治疗重度肾功能不全的急性髓系白血病患者
Am J Hematol. 2023 Sep;98(9):E251-E254. doi: 10.1002/ajh.27012. Epub 2023 Jun 28.
9
Report of four acute myeloid leukemia patients with sustained complete remission with less frequent administration of decitabine and venetoclax.四名急性髓系白血病患者使用地西他滨和维奈克拉给药频率较低却持续完全缓解的报告。
Leuk Lymphoma. 2023 Apr;64(4):897-899. doi: 10.1080/10428194.2023.2179361. Epub 2023 Feb 27.
10
Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy.一线维奈托克联合低甲基化药物治疗失败后急性髓系白血病患者的预后
Haematologica. 2023 Nov 1;108(11):3170-3174. doi: 10.3324/haematol.2022.282677.